Allogeneic Stem Cell Transplantation For T-Cell Lymphoma  by Grosskreutz, C.L. et al.
S284 Poster Session II338
ALLOGENEIC STEM CELL TRANSPLANTATION FOR T-CELL LYMPHOMA
Grosskreutz, C.L., Scigliano, E., Osman, K., Malone, A., Nieto, J.,
Isola, L.M. Mount Sinai Medical Center, New York, NY
Introduction: Results of conventional and even high-dose chemo-
therapy with ASCT for T-cell lymphomas are poor when compared
with their aggressive B-cell counterparts. We analyzed the results of
allogeneic stem cell transplantation in 23 patients with T-cell lym-
phoma at our Institution.
Patients andMethods:Gender: 15 males and 8 females with a me-
dian age of 43 years (19 to 65) underwent allogeneic HCT at
Mount Sinai Medical Center between 5/2000 and 8/2009. The
different histologic subtypes were: 8 PTCL, 6 hepatosplenic
T-cell lymphoma, 4 angioimmunoblastic T-cell lymphoma, 2
CTCL, 1 NK-T cell lymphoma, 1 ATLL, 1 anaplastic T-cell
lymphoma. Donor sources included 15 PBSC, 7 BM and 1 CB.
Donor types were: 13 related and 10 unrelated. Conditioning reg-
imens used were: NST (Flu/TBI200/ATG) 9 pts, RIC (Flu/Mel)
7pts, (Flu/Cy/Campath) 1 pt. and MA (TBI 1,200/Cy) in 6 pts.
Six patients had prior ASCT. The rest received allografting as
primary modality.
Results: Eight patients are alive in CR at a median of 637 days post-
transplant (149-1729). Four of the six patients who underwent prior
ASCT achieved CR after allogeneic HCT. Six patients died of pro-
gressive disease after allogeneic HCT.Nine patients died from com-
plications of GVHD and/or infection.
Conclusions: Allogeneic stem cell transplantation results in dis-
ease-free survival in a fraction of patients with T-cell lymphoma.
Some patients 4/6 achieved CR after allogeneic HCT even after
progression post ASCTx. This observation supports the existence
of clinically-relevant graft versus T-cell lymphoma allo-responses.
Whether this effect exists for all histologic sub-types of T-cell
lymphomas as well as the optimal timing and conditioning for
allografting for this disease are issues that deserve prospective
studies.339
REDUCED INTENSITY CONDITIONING (RIC) REGIMEN BASED ON FLU-
DARABINE (FLU) FOR PATIENTS TREATED WITH ALLO-SCT FOR SEVERE
APLASTIC ANEMIA (SAA)
Abello, V., Rosales, C., Pedraza, E., Linares, A., Esguerra,H., Rosales,M.,
Figueroa, J. Clınica de Marly, Bogota, Colombia
Allo-SCT is the treatment of choice for patients with SAA.
Reduced intensity Conditioning (RIC) has been used in the
past to ensure adequate engraftment and reduce mortality re-
lated to the procedure. Here we report a retrospective analysis
of our experience using a fludarabine based RIC in patients
with SAA.
Since 2006, 12 patients (1 Fanconi Anemia, 11 adquired SAA),
mean 38 years (13-60), 10 males, 2 females, have been treated
with HLA identical related RIC allo-SCT. Conditioning regimen
consisted of Flu (30 mg/m2/day  4 days), Cyclophosphamide
(Cy 10 mg/kg/day  4 days) and horse antithymocyte globuline
(ATG 2 mg/Kg/day  4 days). GVHD prophylaxis consisted in
Ciclosporine and metrotexate for 4 patients, cyclosporine and
MMF for 4 patients and cyclosporine alone in 4 patients. All
grafts were obtained from peripheral blood stem cells. All, but
1 patient, were considered high risk because of more than 20
transfusions before transplantation, co-morbidities (morbid obe-
sity, renal dysfunction, hepatic toxicity), age (3 patients were
over 50) or previous transplant (2 patients had previous second-
ary graft failure after conditioning containing Campath). Mean
time from diagnosis to transplantation was 21.1 months (4.1-
118.7).
One 13 year old patient, with history of multiple infections ex-
pired before stem cell infusion due to severe sepsis. 11 patients en-
grafted, average at 11 days (range 9-16) for neutrophils and 11 days
(range 8-14) for platelets. Transfusion and antibiotic support re-
quired was minimal. None of the patients developed mucositis, di-
arrhea or required parenteral nutrition. Acute GVHD was seen in 2
of evaluable patients; both of them grade IV gastrointestinal
disease, one required ATG treatment due to corticoid refractorydisease. Chronic GVDH was seen in 1 patient who developed
a nephrotic syndrome.
At a mean follow-up of 15 months (range 1-42), 11 patients are
alive and in remission of SAA.
This experience suggests that Flu based RIC protocol allows rapid
and sustained engraftment with minimal early toxicity even in high-
risk patients.
Multicenter prospective clinical trials with longer follow-up are
warranted to confirm our observation.340
REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION CAN ACHIEVE BOTH DISEASE CONTROL AND VERY GOOD
OUTCOMES IN ELDERLY (.60) PATIENTS WITH HEMATOLOGIC MALIG-
NANCIES
Meyers, G., Subbiah, N., Palmbach, G., Kovacsovics, T., Abar, F., Hayes-
Lattin, B., Gajewski, J., Dunn, A., Jacoby, C., Slater, S., Allen, B.,
Maziarz, R. Oregon Health and Science University, Portland, OR
With the rapidly escalating numbers of healthy, elderly patients
with hematologic malignancies, defining optimal therapy for this
patient group is necessary to improve control of the underlying dis-
ease without excess morbidity. The graft vs. malignancy effects as-
sociated with allogeneic hematopoietic stem cell transplantation
(HSCT) may offer disease control with acceptable toxicity. A stan-
dard approach to healthy, elderly patients with high-risk hemato-
logic malignancies involves reduced intensity conditioning
followed by allogeneic HSCT. We report the outcomes of 75 pa-
tients, age 60 to 74, treated with this approach from 2001 through
May 2009.
Conditioning regimens included Fludarabine/TBI (15); TBI
alone (3); Fludarabine/Melphalan (10); and Busulfan/Fludarabine/
TBI (47). Most patients had AML/MDS (53), with the rest compris-
ing NHL (10), CLL (6), CML (3), ALL (2), and plasma cell disorder
(1). Disease control was achieved prior to transplant in a majority of
patients (50 patients in CR, 25 not in CR or untreated). Donors in-
cluded matched unrelated (41) matched related (26), and mis-
matched unrelated (8).
Currently, the outcomes in this high-risk cohort include 47% of
patients are alive. In analyzing cause of death, recurrence accounted
for 38% deaths, with additional deaths from infection (23%),
GVHD (21%), organ failure (15%) and graft failure (1 patient,
3%). Acute GVHD was seen in 64% of patients, with grade 3-4
present in 19% of patients. Of the 65 patients evaluable for chronic
GVHD, 85% had cGVHD, with the majority having extensive
cGVHD. Of particular note, in the 25 patients not in CR at the
time of transplant, 60% were in CR at the last disease status
evaluation.
Outcomes despite aggressive non-transplant treatments in older
patients with hematologic malignancies remain dismal. Two year
survival rates for AML are below 30% due to the high rate of disease
relapse and complications. Alternative treatment options are neces-
sary and increasingly, allogeneic HSCT appears favorable. In this
report, we show very good outcomes in this elderly, high-risk patient
population not dissimilar to younger patients undergoing reduced
intensity transplantation. While relapse remains a large cause of
death in our cohort, it is encouraging to see that 60% of patients
not in CR were able to achieve complete remission in the post-
transplant setting. The goal will be to continue to optimize this treat-
ment approach with improvements in supportive care and disease
control.341
MIXED AUTOLOGOUS AND ALLOGENEIC TRANSPLANTATION, A NEW
MODEL TO ESTABLISH STABLE MIXED CHEIMRSIM
Abedi, M.1, Greer, D.2, Hassani, M.1 1UC Davis Medical Center, Sacra-
mento, CA; 2Roger Williams Medical Center, Providence, RI
Graft versus tumor (GVT) effect after allogeneic bone marrow
transplantation (BMT) for hematological malignancies has a potent
